Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
HZNP Horizon Therapeutics
109.680-0.110-0.10%
Close
02/03 16:00 ET
109.6800.0000.00%
Post Mkt Price 02/03 16:15 ET
High
110.260
Open
109.750
Turnover
248.38M
Low
109.550
Pre Close
109.790
Volume
2.26M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Sold by Creative Planning
Creative Planning reduced its stake in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 18.0% during the 3rd quarter, according to its most recent filing with the Securiti
Horizon Therapeutics Plc
Balyasny Asset Management LP UK Regulatory Announcement: Form 8.3 - Horizon Therapeutics Plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTER
Davidson Kempner Capital Management LP : Form 8.3 - Horizon Therapeutics Plc
Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVERRULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURI
TIAA-CREF UK Regulatory Announcement: Form 8.3 - HORIZON THERAPEUTICS PLC
LONDON--(BUSINESS WIRE)-- FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline
Amgen Inc's (NASDAQ:AMGN) fourth-quarter revenues were $6.84 billion, beating the consensus of $6.76 billion, largely unchanged from Q4 2021, and benefited from a 4% increase in product sales, offset
Amgen Price Target Lowered to $253 From $276 at BMO Capital
FTC Investigating Amgen's Proposed Horizon Therapeutics Buy -- Market Talk
17:47 ET - The Federal Trade Commission is investigating Amgen's proposed $27.8B purchase of rare-disease drugmaker Horizon Therapeutics, the companies say in securities filings. The FTC's antitrust p
Amgen 2023 EPS, Revenue Estimates Within Expectations; Lumakras, Evenity See Big YoY Gains
Amgen, Horizon Therapeutics Receive Second Request for Additional Info From FTC
Company Overview
More
Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
CEO： Mr. Timothy P. Walbert
Market： NASDAQ
Listing Date： 07/28/2011
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet